OBJECTIVES:To evaluate the role of circulating tumor DNA (ctDNA) as a prognostic and predictive biomarker in the perioperative management of muscle-invasive bladder cancer (MIBC). METHODS:We conducted a systematic literature review using PubMed, MEDLINE, and Embase, following PRISMA guidelines. Studies from January 2013 to March 2024 were included if they examined ctDNA in MIBC patients undergoing radical cystectomy (RC) and perioperative chemotherapy or immunotherapy. RESULTS:Eight studies were included. ctDNA detected before RC was associated with poor recurrence-free survival and higher risk of nodal and locally advanced disease. Postoperative ctDNA levels correlated with shorter disease-free survival and higher recurrence rates. ctDNA clearance during neoadjuvant chemotherapy was predictive of treatment response. ctDNA status post-neoadjuvant immunotherapy correlated with pathological outcomes and recurrence rates. CONCLUSIONS:ctDNA is a promising biomarker for predicting oncological outcomes in MIBC, with potential to guide perioperative treatment decisions. Further randomized controlled trials are needed to validate these findings.

Introducción: Hasta hace poco tiempo no existía una terapia adyuvante recomendada para pacientes con metástasis en los ganglios linfáticos (ypN+) después de la quimioterapia neoadyuvante (QNA) y la cistectomía radical (CR) para el cáncer de vejiga músculo invasor (CVMI). El objetivo del estudio fue describir los resultados oncológicos de los pacientes ypN+ tras QNA y CR para CVMI.Métodos: Este estudio retrospectivo colaborativo incluyó a 195 pacientes con enfermedad ypN+ después de QNA seguida de CR y disección bilateral de ganglios linfáticos pélvicos para el CVMI en 7 centros entre 2000 y 2019. Se recopilaron los datos demográficos y las características clínicas y patológicas de los pacientes. Se realizaron análisis de supervivencia con estimaciones de Kaplan-Meier y se generó un modelo de Cox.Resultados: En total, 120 (62%) pacientes fueron pN1, 51 (26%) pN2 y 24 (12%) pN3. Se realizó radioterapia adyuvante en 18 (9%), quimioterapia adyuvante en 40 (21%), y los 137 pacientes restantes (70%) fueron sometidos a observación. La mediana del tiempo de seguimiento fue de 51 meses (IC 95%: 44-62). La mediana de la supervivencia libre de recurrencia, la supervivencia específica al cáncer y la supervivencia global (SG) fue de 18 meses (IC del 95%: 16-21), 47 meses (IC del 95%: 31-70) y 28 meses (IC del 95%: 22-34), respectivamente. En el análisis multivariable, el sexo femenino (HR=1,5; IC 95%: 1,002-2,21; p=0,049) y los márgenes quirúrgicos positivos (HR=1,6; IC 95%: 1,06-2,38; p=0,026) fueron los únicos factores predictivos independientes de la SG. El tipo de tratamiento adyuvante no influyó en la SG (quimioterapia adyuvante, p=0,44; radioterapia adyuvante, p=0,40).Conclusión: Los resultados de supervivencia de los pacientes con CVMI y afectación ganglionar residual tras la QNA y la CR son desfavorecedores. El sexo femenino y los márgenes positivos en la CR se asocian a un pronóstico peor. Estos resultados pueden ser útiles para el diseño de ensayos clínicos a futuro.

Objetivos: Evaluar el papel del ADN tumoral circulante (ctDNA) como biomarcador pronóstico y predictivo en el tratamiento perioperatorio del cáncer de vejiga musculo invasor muscular (CVMI).Métodos: Realizamos una revisión sistemática de la literatura utilizando PubMed, MEDLINE y Embase, siguiendo las directrices PRISMA. Se incluyeron estudios publicados entre enero de 2013 y marzo de 2024 que analizaron el ctDNA en pacientes con CVMI sometidos a cistectomía radical (CR) y a inmunoterapia o quimioterapia perioperatoria.Resultados: Ocho estudios fueron incluidos en la revisión. La detección de ctDNA previa a la CR se asoció con una supervivencia libre de recurrencia baja y un mayor riesgo de enfermedad ganglionar y localmente avanzada. Los niveles de ctDNA en el postoperatorio se correlacionaron con una menor supervivencia libre de enfermedad y mayores tasas de recurrencia. La eliminación de ctDNA durante la quimioterapia neoadyuvante  predijo la respuesta al tratamiento. Los niveles de ctDNA tras la inmunoterapia neoadyuvante se correlacionaron con los resultados patológicos y las tasas de recurrencia.Conclusiones: El ctDNA es un biomarcador prometedor en la predicción de los resultados oncológicos del CVMI, y podría guiar la elección del tratamiento perioperatorio. Se necesitan más ensayos controlados aleatorizados para validar estos hallazgos.

Background and objective Data about the mid- and long-term oncologic outcomes of endoscopic kidney-sparing surgery (eKSS) for upper tract urothelial carcinoma (UTUC) are scarce. Therefore, we aimed to summarize the current evidence on the oncologic outcomes of eKSS for UTUC. Methods A literature search was conducted to identify reports published until May 2024. The Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines were followed to identify eligible studies. The outcomes were the following: recurrence-free (RFS), intravesical recurrence-free (IV-RFS), progression-free (PFS), cancer-specific (CSS), and overall (OS) survival. Key findings and limitations We found 56 studies (n = 52 retrospective) that met our inclusion criteria (n = 2862 patients). The 1-, 2-, 5-, and 10-yr OS rates were 96%, 87%, 80%, and 42%, respectively. The 1-, 2-, 5-, and 10-yr CSS rates were 97%, 89%, 82%, and 69%, respectively. RFS rates at 1, 2, and 5 yr were 69%, 55%, and 45%, respectively. IV-RFS rates at 1, 2, and 5 yr were 80%, 65%, and 64%, respectively. PFS rates at 2 and 5 yr were 75% and 69%, respectively. In low-grade UTUC, OS rates at 2 and 5 yr were 93% and 77%, respectively. The 2- and 5-yr CSS rates were 98% and 88%, respectively. At 2 yr, RFS, IV-RFS, and PFS were 52%, 54%, and 94%, respectively. For high-grade UTUC, only three studies reported data on 2-yr RFS, which was 34%. The main limitation is the heterogeneity found across the studies. Conclusions and clinical implications Local recurrence, bladder recurrence, and progression of UTUC occur mainly within 2 yr after eKSS. After 5-yr follow-up, OS and CSS drop, while the risk of local recurrence is non-negligible.

INTRODUCTION AND OBJECTIVES:Urothelial carcinoma is a challenging disease that requires a comprehensive approach. Multidisciplinary tumor committees are essential to bring specialists together, optimize treatment, ensure individualized care, and promote evidence-based decision making. This study aims to collect evidence and explore the impact of multidisciplinary tumor committees in the management of urothelial carcinoma. MATERIALS AND METHODS:A systematic review was performed following PRISMA guidelines. We searched PubMed/Medline, Embase, Scopus and Cochrane databases for relevant studies on the role of multidisciplinary committees in the management of urothelial carcinoma, including bladder cancer, upper tract urothelial carcinoma and urethral carcinoma. Given the limited and heterogeneous evidence, a systematic review with narrative synthesis was performed. RESULTS:Multidisciplinary tumor committees had a significant impact on the diagnosis and treatment of urothelial neoplasms, especially bladder cancer. Consistent findings showed that these committees produced substantial changes in treatment, improved adherence to clinical guidelines, and demonstrated a potential to improve patient outcomes. In addition, multidisciplinary committees increased the likelihood of curative treatments and were associated with reduced mortality rates, enhanced clinical decision making, and improved patient care, particularly in bladder and upper tract urothelial carcinoma. CONCLUSIONS:This review highlights the essential role of multidisciplinary tumor committees in improving the management of urothelial carcinoma of the bladder and upper urinary tract. However, further research using standardized approaches is needed. The absence of studies on urethral carcinoma underlines the urgent need to investigate the potential benefits of multidisciplinary tumor committees. Future studies should cover a wider range of tumor types and follow standardized methodologies to provide a more complete and generalizable picture.

Introducción y objetivo: Actualmente, el diagnóstico y el tratamiento del carcinoma urotelial del tracto superior (CUTS) se basan en la combinación de la urografía por tomografía computarizada (uro-TAC), la citología y la ureteroscopia (URS). La escasa precisión y las complicaciones asociadas a estas técnicas han motivado el desarrollo de biomarcadores más precisos y no invasivos. El objetivo de este estudio fue revisar y analizar los datos existentes sobre el uso de Bladder EpiCheck® para evaluar su rendimiento en el diagnóstico del CUTS.Material y métodos: Se realizó una búsqueda bibliográfica sobre el valor diagnóstico de Bladder EpiCheck® como biomarcador urinario en el CUTS. Esta búsqueda se realizó en PubMed, Web of Science y Scopus hasta febrero de 2024. Se calcularon los valores agrupados de sensibilidad (S), especificidad (E), valor predictivo negativo (VPN) y valor predictivo positivo (VPP) del biomarcador. El rendimiento diagnóstico se evaluó mediante el área bajo la curva (ABC).Resultados: En el análisis cuantitativo se incluyeron cuatro estudios con 334 pacientes. Bladder EpiCheck® mostró valores diagnósticos agrupados prometedores: S de 0,85(IC95% 0,55-0,96), E de 0,93(IC95% 0,56-0,99), VPP de 0,74(IC95% 0,54-0,87) y VPN de 0,84(IC95% 0,77-0,89). El valor exacto del ABC fue de 0,912.Conclusiones: Bladder EpiCheck® es una herramienta diagnóstica eficaz en el estudio del CUTS, con una elevada precisión diagnóstica, una S y un VPN del 85% y el 84%, respectivamente. Su uso en el diagnóstico y seguimiento del CUTS podría reducir o posponer procedimientos más invasivos, como la URS, minimizando así los riesgos asociados al procedimiento y mejorando la calidad de vida de los pacientes. Aunque se necesitan más investigaciones y estudios prospectivos a gran escala, los resultados actuales indican que Bladder EpiCheck® es una herramienta prometedora para el diagnóstico, la elección del tratamiento y el seguimiento del CUTS.

Introducción y objetivos: El carcinoma urotelial es una enfermedad compleja que requiere un enfoque integral. Los comités multidisciplinares de tumores son esenciales para reunir a los especialistas, optimizar el tratamiento, asegurar una atención individualizada y promover la toma de decisiones basadas en evidencia. Este estudio tiene como objetivo recopilar evidencia y explorar el impacto de los comités multidisciplinares de tumores en el manejo del carcinoma urotelial.Materiales y métodos: Se realizó una revisión sistemática siguiendo las directrices PRISMA. Se buscaron estudios relevantes en las bases de datos PubMed/Medline, Embase, Scopus y Cochrane sobre el papel de los comités multidisciplinares en el manejo del carcinoma urotelial, incluyendo el cáncer de vejiga, el carcinoma urotelial del tracto superior y el carcinoma uretral. Dada la evidencia limitada y heterogénea, se realizó una revisión sistemática con síntesis narrativa.Resultados: Los comités multidisciplinares de tumores influyeron significativamente en el diagnóstico y tratamiento de las neoplasias uroteliales, especialmente en el cáncer de vejiga. Los hallazgos consistentes mostraron que estos comités produjeron cambios significativos en el tratamiento, mejoraron el cumplimiento de las guías clínicas y demostraron un potencial para mejorar los resultados en los pacientes. Además, los comités multidisciplinares aumentaron la probabilidad de tratamientos curativos y se asociaron con una reducción en las tasas de mortalidad, una mejor toma de decisiones clínicas y una mejor atención al paciente, particularmente en el carcinoma urotelial de vejiga y del tracto superior.Conclusiones: Esta revisión destaca el papel fundamental de los comités multidisciplinares de tumores en la mejora del manejo del carcinoma urotelial de vejiga y del tracto superior. No obstante, es necesario realizar más investigaciones utilizando enfoques estandarizados. La ausencia de estudios sobre el carcinoma uretral pone de manifiesto la necesidad urgente de investigar los posibles beneficios de los comités multidisciplinares de tumores. Los estudios futuros deberían abarcar una gama más amplia de tipos de tumores y adoptar metodologías uniformes para proporcionar una visión más completa y generalizable.

Introduction and objective: Current upper tract urothelial carcinoma (UTUC) diagnosis and disease management rely on the combination of CT Urography (CTU), cytology and ureteroscopy (URS). The limited accuracy and complications associated with these tools have led to the search for non-invasive and reliable biomarkers. Our aim was to review and analyse the existing data on the use of Bladder EpiCheck (R) to assess its performance as a diagnostic tool for UTUC. Material and methods: A literature search on the diagnostic value of Bladder EpiCheck (R) as a urinary biomarker in UTUC was conducted through PubMed, Web of Science and Scopus until February 2024. Pooled sensitivity (Se), specificity (Sp), negative predictive value (NPV) and positive predictive value (PPV) of the biomarker were calculated. Diagnostic performance was assessed through the area under the curve (AUC). Results: Four studies, including 334 patients, were included in the quantitative analysis. Bladder EpiCheck (R) showed promising pooled diagnostic values with Se of 0.85 (95% CI: 0.55-0.96), Sp of 0.93 (95% CI: 0.56-0.99), PPV of 0.74 (95% CI: 0.54-0.87) and NPV of 0.84 (95% CI: 0.77-0.89). The exact AUC obtained was 0.912. Conclusions: Bladder EpiCheck (R) is an effective diagnostic tool in UTUC, showing a promising diagnostic accuracy, with a Se and NPV of 85% and 84%, respectively. Its use in UTUC diagnosis and follow-up could reduce or postpone the need for more invasive procedures, such as URS, thereby reducing the procedure-associated risks and improving patients' quality of life. Although further research and large prospective studies are needed, the current results indicate that Bladder EpiCheck (R) is a promising tool in UTUC diagnosis, treatment decision-making, and follow-up. (c) 2025 AEU. Published by Elsevier Espana, S.L.U. All rights are reserved, including those for text and data mining, AI training, and similar technologies.

You have accessJournal of UrologyBladder Cancer: Invasive I (PD02)1 May 2024PD02-05 THE IMPACT OF VENOUS THROMBOEMBOLISM ON MUSCLE INVASIVE BLADDER CANCER (MIBC) PATIENTS UNDERGOING OPEN OR MINIMALLY-INVASIVE RADICAL CYSTECTOMY IN THE UNITED STATES: PERIOPERATIVE OUTCOMES AND HEALTH-CARE COSTS FROM INSURANCE CLAIMS DATA Francesco Del Giudice, Anas Tresh, Ettore De Berardinis, Vincenzo Asero, Carlo Maria Scornajenghi, Satvir Basran, Federico Belladelli, Gian Maria Busetto, Matteo Ferro, Felice Crocetto, Biagio Barone, Benjamin Pradere, Wojciech Krajewski, Lukasz Nowak, Marco Moschini, Abhay Rane, Ben Challacombe, Rajesh Nair, and Benjamin I. Chung Francesco Del GiudiceFrancesco Del Giudice , Anas TreshAnas Tresh , Ettore De BerardinisEttore De Berardinis , Vincenzo AseroVincenzo Asero , Carlo Maria ScornajenghiCarlo Maria Scornajenghi , Satvir BasranSatvir Basran , Federico BelladelliFederico Belladelli , Gian Maria BusettoGian Maria Busetto , Matteo FerroMatteo Ferro , Felice CrocettoFelice Crocetto , Biagio BaroneBiagio Barone , Benjamin PradereBenjamin Pradere , Wojciech KrajewskiWojciech Krajewski , Lukasz NowakLukasz Nowak , Marco MoschiniMarco Moschini , Abhay RaneAbhay Rane , Ben ChallacombeBen Challacombe , Rajesh NairRajesh Nair , and Benjamin I. ChungBenjamin I. Chung View All Author Informationhttps://doi.org/10.1097/01.JU.0001008836.73392.92.05AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Interplay between Venous Thromboembolism (VTE) and solid malignancy is established. With rising projected rates of bladder cancer (BCa) and increasing number of patients experiencing BCa and VTE, our aim is to assess the impact of a preoperative VTE diagnosis on perioperative outcomes and health-care costs in MIBC undergoing Radical Cystectomy (RC). METHODS: Patients≥18 y/o with BCa undergoing Open or Minimally Invasive (MIS) RC were identified in the MerativeTM Marketscan® Research Databases between 2007 and 2021. The association of VTE history with 90-day complication rates, postoperative VTE events, rehospitalization, and total hospital costs (2021 US dollars) was determined by multivariable logistic regression modeling adjusted for patient and perioperative confounders. Sensitivity analysis on VTE degree of severity (i.e., pulmonary embolism [PE] and/or peripheral deep [DVT] or superficial venous thrombosis) was examined. RESULTS: Out of n=8,759 RC procedures, n=743 (8.48%) had a previous history for any VTE including n=245 (32.97%) PE, n=339 (45.63%) DVT and n=59 (21.40%) superficial VTE. Overall, history of VTE before RC was strongly associated with almost any worse postoperative outcomes including higher risk for any and apparatus-specific 90-days postoperative complications (Odds Ratio [OR]: 1.23, 95% Confidence Interval [CI], 1.03-1.46). Subsequent incidence of new VTE events (OR: 7.02, 95% CI: 5.93-8.31), rehospitalization (OR: 1.25, 95% CI: 1.06-1.48), other than home/self-care discharge status (OR: 1.53, 95% CI: 1.28-1.82), and higher health-care costs related to the RC procedure (OR: 1.43, 95% CI: 1.22-1.68) were significantly correlated with VTE history. Importantly, the association was maintained regardless the severity of VTE history (i.e., PE, DVT or phlebitis/thrombophlebitis). CONCLUSIONS: Experiencing VTE before RC for MIBC significantly raises the risk of any worse perioperative outcomes regardless the severity of the VTE event. These findings will likely have an impact in BCa counseling on the risks of surgery and will improve our ability to mitigate such risks. Download PPT Source of Funding: None © 2024 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 211Issue 5SMay 2024Page: e71 Advertisement Copyright & Permissions© 2024 by American Urological Association Education and Research, Inc.Metrics Author Information Francesco Del Giudice More articles by this author Anas Tresh More articles by this author Ettore De Berardinis More articles by this author Vincenzo Asero More articles by this author Carlo Maria Scornajenghi More articles by this author Satvir Basran More articles by this author Federico Belladelli More articles by this author Gian Maria Busetto More articles by this author Matteo Ferro More articles by this author Felice Crocetto More articles by this author Biagio Barone More articles by this author Benjamin Pradere More articles by this author Wojciech Krajewski More articles by this author Lukasz Nowak More articles by this author Marco Moschini More articles by this author Abhay Rane More articles by this author Ben Challacombe More articles by this author Rajesh Nair More articles by this author Benjamin I. Chung More articles by this author Expand All Advertisement PDF downloadLoading ...

You have accessJournal of UrologyBladder Cancer: Epidemiology & Evaluation II (MP35)1 May 2024MP35-11 LONG-TERM ONCOLOGICAL OUTCOMES OF DE NOVO BLADDER CANCER IN KIDNEY TRANSPLANT RECIPIENTS: RESULTS FROM A LARGE MULTICENTER INTERNATIONAL COHORT Simone Livoti, Francesco Soria, Matteo Rosazza, Daniele Dutto, Fulvia Colucci, David D'Andrea, Ekaterina Laukhtina, Jeremy Teoh, Gautier Marcq, Denis Séguier, Renate Pichler, Felizian Lackner, Robin Martin, Thierry Roumeguere, Simone Albisinni, Benoit Mesnard, Wojciech Krajewski, Shahrokh Shariat, and Paolo Gontero Simone LivotiSimone Livoti , Francesco SoriaFrancesco Soria , Matteo RosazzaMatteo Rosazza , Daniele DuttoDaniele Dutto , Fulvia ColucciFulvia Colucci , David D'AndreaDavid D'Andrea , Ekaterina LaukhtinaEkaterina Laukhtina , Jeremy TeohJeremy Teoh , Gautier MarcqGautier Marcq , Denis SéguierDenis Séguier , Renate PichlerRenate Pichler , Felizian LacknerFelizian Lackner , Robin MartinRobin Martin , Thierry RoumeguereThierry Roumeguere , Simone AlbisinniSimone Albisinni , Benoit MesnardBenoit Mesnard , Wojciech KrajewskiWojciech Krajewski , Shahrokh ShariatShahrokh Shariat , and Paolo GonteroPaolo Gontero View All Author Informationhttps://doi.org/10.1097/01.JU.0001009372.61513.54.11AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Kidney transplant recipients face higher bladder cancer risk (BCa) than the general population. Moreover, these patients tend to manifest a more aggressive form of BCa, being often diagnosed at a more advanced stage and with higher-grade tumors than non-transplanted ones. Limited evidence exists on long-term outcomes, mostly from national registries or small retrospective series. This study aims to outline the characteristics and the oncological outcomes of de novo BCa in kidney transplant recipients in a large retrospective multicenter international cohort. METHODS: This was a multicenter retrospective collaboration involving 8 international referral centers. Kidney transplant recipients with de novo BCa diagnosed between 2000 and 2022 were included. The primary endpoint was to report tumor features at presentation and long-term oncological outcomes, focusing on recurrence-free (RFS), progression-free (PFS), cystectomy-free (CFS) and overall survival (OS). RESULTS: Overall, 89 patients were included. Median age at BCa diagnosis was 64 years (IQR 56-68), with a median time from kidney transplantation to BCa diagnosis of 98 months (IQR 50-161). At the time of presentation, the majority of patients were found to have muscle-invasive disease (61% vs 39%). Clinical tumor stage at diagnosis was cTa, cT1, cT2, cT3 and cT4 in 25 (29%), 9 (10%), 27 (31%), 25 (29%) and 1 (1%) patients, respectively. Overall, 33 (37%) patients underwent immediate radical cystectomy. Among the remaining 66 patients, 28 (42%) received intravesical adjuvant therapy (18 BCG and 10 chemotherapy), and subsequent disease recurrence and progression were observed in 21 (38%) and 5 (9%) of them, respectively. Ultimately, 13 (20%) of these patients required delayed radical cystectomy. The OS rates at 1, 3, and 5 years were 78%, 53%, and 47%, respectively. CONCLUSIONS: To our knowledge, this is largest series to date reporting long-term oncological outcomes in kidney transplant recipients who developed de novo BCa. Our findings confirm the aggressive nature of BCa in transplanted patients. Notably, a significant proportion of patients presented with muscle-invasive disease, a higher rate compared to non-transplanted BCa cases. Furthermore, our data highlight a substantial risk of disease progression in patients initially diagnosed with non-muscle invasive BCa. These results offer valuable insights for guiding the management of BCa in this unique patient population and underscore the importance of tailored strategies for optimal patient care. Source of Funding: None © 2024 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 211Issue 5SMay 2024Page: e585 Advertisement Copyright & Permissions© 2024 by American Urological Association Education and Research, Inc.Metrics Author Information Simone Livoti More articles by this author Francesco Soria More articles by this author Matteo Rosazza More articles by this author Daniele Dutto More articles by this author Fulvia Colucci More articles by this author David D'Andrea More articles by this author Ekaterina Laukhtina More articles by this author Jeremy Teoh More articles by this author Gautier Marcq More articles by this author Denis Séguier More articles by this author Renate Pichler More articles by this author Felizian Lackner More articles by this author Robin Martin More articles by this author Thierry Roumeguere More articles by this author Simone Albisinni More articles by this author Benoit Mesnard More articles by this author Wojciech Krajewski More articles by this author Shahrokh Shariat More articles by this author Paolo Gontero More articles by this author Expand All Advertisement PDF downloadLoading ...

Introduction The ILY robotic flexible ureteroscope has been introduced in order to improve intraoperative ergonomics, reduce operator distance from radiation and shorten the learning curve. In this study we aimed to assess the clinical performance and feasibility of the ILY robot during retrograde intrarenal surgery (RIRS) and combined endoscopic procedures (miniECIRS). Material and methods The RIRS procedures were performed using the ILY robotic arm in 57 adult patients (46 RIRS and 11 miniECIRS) from 2022 to 2023. All procedures were performed in the supine position. Pre-stenting was not the standard of care. Results Turning on and calibration of the device took approximately 100 s. Average draping time was 93 s using original ILY drapes and 47 s using classic drapes designed for C-arm covering. Mean docking time was 73 s in procedures with ureteral access sheath (UAS) and 61 s in procedures without it. The undocking took less than 60 s in every case. Average procedure time was 63 min for RIRS and 55 min for miniECIRS. Endoscopically proven stone-free rate was achieved in 37 (80.4%) RIRS and 10 (90.9%) miniECIRS patients. A total of 17 (36.9%) RIRS and 8 (72.7%) miniECIRS procedures required conversion in order to perform basketing and stone fragments retrieval/transposition. Conclusions The use of ILY robot during endourological procedures is feasible and urologists that are familiar with the device controller do not require extensive training. The time needed for device draping, docking and undocking was approximately 4 minutes. Moreover, use of the robot resulted in satisfactory stone-free rates.